Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

3T, Cryogen-Free MRI/PET and 3T MRI/SPECT Developed for Research Applications

By BiotechDaily International staff writers
Posted on 26 Sep 2013
Image: The MR Solutions’ range of benchtop, preclinical, 3T cryogen-free MRI scanners provide superior soft tissue contrast and molecular imaging capability, and can be easily accommodated within an existing laboratory (Photo courtesy of MR Solutions).
Image: The MR Solutions’ range of benchtop, preclinical, 3T cryogen-free MRI scanners provide superior soft tissue contrast and molecular imaging capability, and can be easily accommodated within an existing laboratory (Photo courtesy of MR Solutions).
Combined 3T, cryogen-free magnetic resonance imaging/positron emission tomography (MRI/PET) and a 3T MRI/single photon emission computed tomography (SPECT) technology has been developed for multimodality imaging applications for researchers.

MR Solutions (Guilford, Surrey, UK), a developer of preclinical scanning technology, launched the first combined cryogen-free, 3T, MRI/PET and the first 3T, MRI/SPECT scanners at the World Molecular Imaging Conference (WMIC) in Savannah, GA, USA, September 18–21, 2013.

Dr. David Taylor, CEO of MR Solutions, commented, “The combination of high-resolution PET or SPECT with high-performance cryogen-free MRI will provide significant benefits both for academia and pharma. These systems offer researchers for the first time simultaneous multimodality imaging hitherto not commercially available. It is yet another development in our plan to provide the best quality images and functional data in a way that makes it quicker and easier for scientists to work with animals.”

To provide the SPECT images MR Solutions has devised a system where the three gamma camera heads and focusing collimator can be easily clipped on to the front of the bore of the MRI scanner to provide cutting-edge 3D SPECT images. The SPECT images can be registered with the MRI images, providing anatomic-functional combined capability. Moreover, the SPECT gamma camera can be used independently.

The PET capability is provided by new solid-state detectors and ASIC (application-specific integrated circuit) technology, which is integrated in the bore of the MRI scanner. The scanner combines the exquisite structural and functional characterization of tissue provided by MRI with the extreme sensitivity of PET imaging for metabolism and tracking of uniquely labeled cell types or cell receptors. This is especially helpful in cardiology, oncology, and neurology research.

MR Solutions’ range of cryogen-free, benchtop, 3T MRI scanners (16-, 31-, and 72-cm bores), which were only launched at the beginning of 2013, has been a transformative in the field of preclinical scanning. The new technology not only provides excellent soft tissue contrast and high spatial resolution, a vastly reduced stray magnetic field and all the benefits that brings but also allows the magnetic field strength to be easily varied.

Related Links:

MR Solutions



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.